APA (7th ed.) Citation

Y, M., K, S., N, T., K, Y., M, C., T, I., . . . M, N. (2026). PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation. Leukemia. https://doi.org/10.1038/s41375-026-03055-5

Chicago Style (17th ed.) Citation

Y, Mori, et al. "PLK1 Inhibition Enhances Brentuximab Vedotin Efficacy in CD30-positive T-cell Lymphoma via Spindle Assembly Checkpoint Activation." Leukemia 2026. https://doi.org/10.1038/s41375-026-03055-5.

MLA (9th ed.) Citation

Y, Mori, et al. "PLK1 Inhibition Enhances Brentuximab Vedotin Efficacy in CD30-positive T-cell Lymphoma via Spindle Assembly Checkpoint Activation." Leukemia, 2026, https://doi.org/10.1038/s41375-026-03055-5.